-
Patent Agency Ranking
公开(公告)号：US20230288415A1
公开(公告)日：2023-09-14
申请号：US18062937
申请日：2022-12-07
Inventor： Edward K. Wakeland , David E. Gerber , Quanzhen Li , Shaheen Khan , Saad Khan , Yang Xie , Jason Y. Park , Farjana Fattah , Xin Luo
IPC: G01N33/564 , G01N33/68
CPC classification number: G01N33/564 , G01N33/6863 , G01N2800/24 , G01N2800/52 , G01N2800/60
Abstract: The present disclosure is directed to methods and compositions for the prediction and treatment of immunotherapy-induced toxicities, as well as improved methods for the treatment of cancer with immunotherapies.
-
公开(公告)号：US11747345B2
公开(公告)日：2023-09-05
申请号：US16487335
申请日：2018-02-19
Inventor： David E. Gerber , Edward Wakeland , Quan Li , Saad Khan , Jason Y. Park , Xin Luo , Yang Xie
CPC classification number: G01N33/6854 , C07K16/2818 , G01N2800/24
Abstract: The present disclosure is directed to methods and compositions for the prediction and treatment of immunotherapy-induced toxicities, as well as improved methods for the treatment of cancer with immunotherapies.
-
公开(公告)号：US20210263045A1
公开(公告)日：2021-08-26
申请号：US17045482
申请日：2019-04-08
Inventor： Edward WAKELAND , David E. GERBER , Quan LI , Shaheen KHAN , Saad KHAN , Yang XIE , Jason Y. Park , Farjana FATTAH , Xin LUO
IPC: G01N33/68 , G01N33/564 , C07K16/28
Abstract: The present disclosure is directed to methods and compositions for the prediction and treatment of immunotherapy—induced toxicities, as well as improved methods for the treatment of cancer with immunotherapies.
-
4.发明公开公开(公告)号：US20240150836A1
公开(公告)日：2024-05-09
申请号：US18504868
申请日：2023-11-08
Inventor： Jason Y. Park , John David Farrar , David E. Gerber , Farjana Fattah , Hong Mu-Mosley
IPC: C12Q1/6883 , G01N33/564 , G01N33/569 , G01N33/68
CPC classification number: C12Q1/6883 , G01N33/564 , G01N33/56972 , G01N33/6863 , C12Q2600/118 , C12Q2600/158 , G01N2800/24
Abstract: The present disclosure generally relates to compositions and methods for predicting or diagnosing immune-related adverse events (irAE) before, during, or after immune checkpoint inhibitor (ICI) treatment in a subject with cancer. The method includes assessment of transcripts, autoantibody levels, cytokine levels, and immune cells. The irAE can be ICI-related myositis, ICI-related myocarditis or ICI-related myositis and myocarditis.
-
公开(公告)号：US20240077496A1
公开(公告)日：2024-03-07
申请号：US18338997
申请日：2023-06-21
Inventor： David E. Gerber , Edward Wakeland , Quan Li , Saad Khan , Jason Y. Park , Xin Luo , Yang Xie
CPC classification number: G01N33/6854 , C07K16/2818 , G01N2800/24
Abstract: The present disclosure is directed to methods and compositions for the prediction and treatment of immunotherapy-induced toxicities, as well as improved methods for the treatment of cancer with immunotherapies.
-
-
-
-
Search Results
5
records
(took 0.019 seconds)
